Thomas E W, Nishizawa E E, Zimmermann D C, Williams D J
Upjohn Company, Kalamazoo, Michigan 49001.
J Med Chem. 1989 Jan;32(1):228-36. doi: 10.1021/jm00121a041.
Routine screening of compounds for inhibition of ADP-induced platelet aggregation in vitro revealed that 1,1'-hexamethylenebis[3-cyclohexyl-3-[(cyclohexylimino) (4-morpholinyl) methyl]urea] (1) was active and represented the first example of a bis(acylguanidine) with possible antithrombotic activity. In order to develop a structure-activity relationship for this class of compounds, we synthesized a number of new bis(acylguanidines). These were tested in vitro, and several analogues were also active. Ex vivo testing revealed that compounds 22, 41, 58, and 70-73 were orally active in rats or guinea pigs.
对化合物进行常规体外筛选以检测其对ADP诱导的血小板聚集的抑制作用,结果显示1,1'-亚己基双3-环己基-3-[(环己基亚氨基)(4-吗啉基)甲基]脲具有活性,是具有潜在抗血栓活性的双(酰基胍)的首个实例。为了建立这类化合物的构效关系,我们合成了一些新的双(酰基胍)。对它们进行了体外测试,发现有几种类似物也具有活性。体内测试表明,化合物22、41、58以及70 - 73在大鼠或豚鼠体内口服具有活性。